Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.
Choc
M G
MG
Novartis Pharmaceuticals Corp., East Hanover, New Jersey 07936, USA.
Mueller
E A
EA
Robinson
W T
WT
Kumle
A
A
Smith
H T
HT
Charnick
S B
SB
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D001189:Aryl Hydrocarbon Hydroxylases; D001682:Biological Availability; D001711:Biotransformation; D018592:Cross-Over Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004304:Dosage Forms; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D065607:Cytochrome P-450 Enzyme Inhibitors; D004304:Dosage Forms; D007166:Immunosuppressive Agents; D011500:Protein Synthesis Inhibitors; D016572:Cyclosporine; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating